KRRO Korro Bio, Inc.

8-K Current Report

Filed: March 12, 2026

Health Care

Pharmaceutical Preparations

Korro Bio, Inc. (KRRO) 8-K current report filed with SEC EDGAR on March 12, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 2.02: Results of Operations and Financial Condition

AI Filing Analysis
8-K

Item 2.02 · Results of Operations and Financial Condition

• Full-year 2025 financial results released March 12, 2026 — details in Exhibit 99.1
• KRRO is a clinical-stage biotech; cash runway and R&D spend are key metrics to watch in the release

Other Korro Bio, Inc. 8-K Filings

8-K Mar 9, 2026

Get deeper insights on Korro Bio, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.